D-0591-2025 Class II Ongoing

Recalled by PFIZER INC — New York, NY

FDA drug recall D-0591-2025 was initiated by PFIZER INC on Aug 4, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility. The recall status is ongoing. Affected quantity: 15,750 vials.

Recall details

Product Type
Drugs
Report Date
Aug 27, 2025
Initiation Date
Aug 4, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
15,750 vials

Product description

Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-6637-24. Case NDC: 00409-6637-14.

Reason for recall

Lack of Assurance of Sterility.

Distribution pattern

U.S. Nationwide

Code information

Lot #: LH2671, Exp. 11/30/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0591-2025
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for PFIZER INC? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0591-2025. Report a data issue: hello@regdatalab.com.